NICE has recommended teduglutide (Revestive) in final draft guidance for people with short bowel syndrome who are aged 1 year and above and are in a stable condition following surgery to remove an abnormal bowel.
According to NICE final draft guidance, fenfluramine, when added to standard care medicines, reduces the number of convulsive seizures people have. It may also be more effective than cannabidiol plus clobazam in reducing the number of seizures when used with 2 other antiepileptic medicines.
NICE did not recommend esketamine due to limitations in the clinical evidence and economic model and has called for further research to address some of the uncertainties.
We and selected partners, use cookies or similar technologies as specified in the cookie policy and privacy policy.
You can consent to the use of such technologies by closing this notice.
Cookie Control
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used
to help us achieve the features and activities described below. To learn more about how these trackers help us
and how they work, refer to the cookie policy. You may review and change your preferences at any time.
These trackers are used for activities that are strictly necessary to operate or deliver the service you requested from us and, therefore, do not require you to consent.
These trackers help us to provide a personalized user experience by improving the quality of your preference management options, and by enabling the interaction with external networks and platforms.